Table 2.
Tumour visibility on DBT + FFDM and Clinicopathologic variables: Univariate analysis
| Clinicopathologic variables | Total (n = 106) | Tumour visibility on DBT + FFDM | |||
| 1 (n = 22) | 2 (n = 11) | 3 (n = 73) | P-value a | ||
| Age (years) | |||||
| Mean ± SD | 52.2 ± 11.4 (range 22–77) | 47.6 ± 7.9 | 50.6 ± 8.2 | 53.9 ± 12.3 | 0.078 |
| Tumour size(mm) b | |||||
| Mean ± SD | 14.6 ± 4.6 (range 4–20) | 12.7 ± 5.1 | 12.7 ± 3.4 | 14.1 ± 4.6 | 0.728 |
| Tumour histology | |||||
| Ductal | 97 (91.5) | 18 (81.8) | 11 (100.0) | 68 (93.2) | 0.396 |
| Lobular | 5 (4.7) | 2 (9.1) | 0 (0) | 3 (4.1) | |
| Others c | 4 (3.8) | 2 (9.1) | 0 (0) | 2 (2.7) | |
| Histologic grade | |||||
| 1or 2 | 55 (51.9) | 13 (59.1) | 7 (63.6) | 35 (47.9) | 0.468 |
| 3 | 51 (48.1) | 9 (40.9) | 4 (36.4) | 38 (52.1) | |
| KI-67 (%) | |||||
| ≤14 | 95 (89.6) | 20 (90.9) | 11 (100) | 64 (87.7) | 0.222 |
| >14 | 11 (10.4) | 2 (9.1) | 0 (0) | 9 (12.3) | |
| IHC subtype | |||||
| ER-positive | 86 (81.1) | 20 (90.9) | 9 (81.8) | 57 (78.1) | 0.318 |
| HER2-enriched | 10 (9.4) | 2 (9.1) | 0 (0) | 8 (11.0) | |
| Triple negative | 10 (9.4) | 0 (0) | 2 (18.2) | 8 (11.0) | |
DBT, digital breast tomosynthesis; FFDM, full-field digital mammography; SD, standard deviation; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immuno histo chemistry.
Data are numbers of cases, and data in parentheses are percentages.
P-values were obtained by the Pearson’s Chi-square test or Fisher’s exact test for categorical variables and Mann-Whitney test for continuous variables. P-value < 0.050 was considered to indicate a statistically significant difference.
Determined by the greatest dimension of the invasive tumour on the basis of the surgically excised specimens.
Papillary (n = 2, 1.9%), mucinous (n = 1, 0.9%), and tubular (n = 1, 0.9%) cancers.